Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR411298 adjunctive treatment for persistent cancer pain
2011-002557-56Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer pain and breakthrough cancer pain (BTcP) comparing SSR411298 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Change from baseline to end of treatment in pain intensity on the Numeric Rating Scale. Started Jul 2011; status: terminated.
02
Drugs
SSR411298
03
Conditions
cancer painbreakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on 2011-002557-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002557-56.